2-methyl-5-(2-nitrophenoxy)pyridine | 76167-52-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-methyl-5-(2-nitrophenoxy)pyridine
• CAS: 76167-52-7
• 化学式: C₁₂H₁₀N₂O₃
• 分子量: 230.223
• InChiKey: LQKWEJCLFUSJRI-UHFFFAOYSA-N

物化性质

• 沸点：
  138-140 °C(Press: 0.2 Torr)
• 密度：
  1.269±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  67.9
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-methyl-5-(2-nitrophenoxy)pyridine 在 铁粉 、 溶剂黄146 作用下， 反应 1.0h， 以95%的产率得到2-<(6-methyl-3-pyridinyl)oxy>benzenamine
  参考文献：
  名称：

  Cognition-activating properties of 3-(aryloxy)pyridines

  摘要：

  A series of 3-(aryloxy)pyridines was found to possess activity in enhancing retention for passive avoidance learning in mice. This test was used to select compounds with potential therapeutic properties for the treatment of cognitive disorders. Reference drugs that gave positive results in this procedure included d-amphetamine, magnesium pemoline, methyl phenidate, picrotoxin, phenytoin, and ethosuximide. All active compounds gave inverted U-shaped dose-response curves. The most active compounds of the 3-(aryloxy)pyridines included 3-phenoxypyridine (1), 3-(2-fluorophenoxy)pyridine (2), 3-(4-fluorophenoxy)pyridine (4), 3,3'-oxybis(pyridine) (23), and 3,3'-oxybis(pyridine) 1-oxide (24). 3-Phenoxypyridine (1) was clearly superior to all of the analogues tested in terms of the level of retention, grammometric potency, and the breadth of its inverted U-shaped dose-response curve. It was given the designation of CI-844 and after a detailed study of its pharmacological profile was submitted for preclinical toxicology.

  DOI：

  10.1021/jm00135a020
• 作为产物：
  描述：

  3-羟基-6-甲基吡啶 、 硝基氯苯 在 铜 、 sodium hydride 作用下， 生成 2-methyl-5-(2-nitrophenoxy)pyridine
  参考文献：
  名称：

  Cognition-activating properties of 3-(aryloxy)pyridines

  摘要：

  A series of 3-(aryloxy)pyridines was found to possess activity in enhancing retention for passive avoidance learning in mice. This test was used to select compounds with potential therapeutic properties for the treatment of cognitive disorders. Reference drugs that gave positive results in this procedure included d-amphetamine, magnesium pemoline, methyl phenidate, picrotoxin, phenytoin, and ethosuximide. All active compounds gave inverted U-shaped dose-response curves. The most active compounds of the 3-(aryloxy)pyridines included 3-phenoxypyridine (1), 3-(2-fluorophenoxy)pyridine (2), 3-(4-fluorophenoxy)pyridine (4), 3,3'-oxybis(pyridine) (23), and 3,3'-oxybis(pyridine) 1-oxide (24). 3-Phenoxypyridine (1) was clearly superior to all of the analogues tested in terms of the level of retention, grammometric potency, and the breadth of its inverted U-shaped dose-response curve. It was given the designation of CI-844 and after a detailed study of its pharmacological profile was submitted for preclinical toxicology.

  DOI：

  10.1021/jm00135a020

文献信息

• BUTLER D. E.; POSCHEL B. P. H.; MARRIOTT J. G., J. MED. CHEM., 1981, 24, NO 3, 346-350
  作者：BUTLER D. E.、 POSCHEL B. P. H.、 MARRIOTT J. G.

  DOI：——

  日期：——
• Cognition-activating properties of 3-(aryloxy)pyridines
  作者：Donald E. Butler、B. P. H. Poschel、John G. Marriott

  DOI：10.1021/jm00135a020

  日期：1981.3

  A series of 3-(aryloxy)pyridines was found to possess activity in enhancing retention for passive avoidance learning in mice. This test was used to select compounds with potential therapeutic properties for the treatment of cognitive disorders. Reference drugs that gave positive results in this procedure included d-amphetamine, magnesium pemoline, methyl phenidate, picrotoxin, phenytoin, and ethosuximide. All active compounds gave inverted U-shaped dose-response curves. The most active compounds of the 3-(aryloxy)pyridines included 3-phenoxypyridine (1), 3-(2-fluorophenoxy)pyridine (2), 3-(4-fluorophenoxy)pyridine (4), 3,3'-oxybis(pyridine) (23), and 3,3'-oxybis(pyridine) 1-oxide (24). 3-Phenoxypyridine (1) was clearly superior to all of the analogues tested in terms of the level of retention, grammometric potency, and the breadth of its inverted U-shaped dose-response curve. It was given the designation of CI-844 and after a detailed study of its pharmacological profile was submitted for preclinical toxicology.